Overview
Kodiak Q2 net loss of $54.3 mln missed analyst expectations
Operating income for Q2 beat estimates, driven by clinical study activities
Cash position at $104.2 mln, supporting operations into 2026
Result Drivers
CLINICAL TRIALS - Increased R&D expenses driven by active Phase 3 studies for tarcocimab, KSI-501, and KSI-101
CASH POSITION - Cash reserves of $104.2 mln expected to support operations into 2026
MANUFACTURING - Completion of commercial-scale batches at URSUS facility for upcoming BLA submissions
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| -$1.03 |
|
Q2 Net Income | Miss | -$54.31 mln | -$53.70 mln (3 Analysts) |
Q2 Operating Income | Beat | -$55.51 mln | -$57.60 mln (4 Analysts) |
Q2 Basic EPS |
| -$1.03 |
|
Q2 Operating Expenses |
| $55.51 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Kodiak Sciences Inc is $3.50, about 143.4% below its August 12 closing price of $8.52
Press Release: ID:nPnbpvHTFa